ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
2.0503
Bid
2.05
Ask
2.36
Volume
151
0.00 Day's Range 0.00
1.57 52 Week Range 4.08
Market Cap
Previous Close
2.12
Open
-
Last Trade Time
08:00:02
Financial Volume
-
VWAP
-
Average Volume (3m)
21,944
Shares Outstanding
8,538,883
Dividend Yield
-
PE Ratio
-5.33
Earnings Per Share (EPS)
-1.81
Revenue
-
Net Profit
-15.42M

About Indaptus Therapeutics Inc

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, ... Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. Show more

Sector
Medicinal Chems,botanicl Pds
Industry
Medicinal Chems,botanicl Pds
Headquarters
Wilmington, Delaware, USA
Founded
1970
Indaptus Therapeutics Inc is listed in the Medicinal Chems,botanicl Pds sector of the NASDAQ with ticker INDP. The last closing price for Indaptus Therapeutics was $2.12. Over the last year, Indaptus Therapeutics shares have traded in a share price range of $ 1.57 to $ 4.08.

Indaptus Therapeutics currently has 8,538,883 shares outstanding. The market capitalization of Indaptus Therapeutics is $18.10 million. Indaptus Therapeutics has a price to earnings ratio (PE ratio) of -5.33.

INDP Latest News

Indaptus Therapeutics to Present Positive Data on Lead Product Candidate, Decoy20, at STING & TLR-Targeted Therapies Summit

- Chief Scientific Officer Dr. Newman to present initial clinical data that further validates Company’s “Pulse-Prime” hypothesis - Dr. Newman also named Chair of the Summit NEW YORK, June 11...

Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection...

Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20

Latest data from first and second cohorts support Company’s 'pulse-prime' approach, demonstrating rapid clearance, broad immune activation, and encouraging safety profile Poster Presented at...

Indaptus Therapeutics to Present at the Jefferies Global Healthcare Conference

NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection...

Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.1297-5.94954128442.182.472.0471732.14392466CS
4-0.2597-11.24242424242.312.472.0492802.20692079CS
12-0.2097-9.278761061952.263.11.9719219442.49381049CS
260.350320.60588235291.73.11.57538692.347928CS
520.300317.161.754.081.57356472.37115782CS
156-8.0497-79.710.128.82991.254310459.27917072CS
260-8.0497-79.710.128.82991.254310459.27917072CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NUZENuZee Inc
$ 4.26
(313.59%)
24.19M
DRMADermata Therapeutics Inc
$ 3.45
(165.38%)
20.02M
BBLGBone Biologics Corporation
$ 2.149
(71.92%)
8.85M
PIRSPieris Pharmaceuticals Inc
$ 13.65
(71.05%)
1.16M
HOTHHoth Therapeutics Inc
$ 1.43
(47.13%)
19.49M
CONNConns Inc
$ 0.3202
(-36.84%)
236.16k
NUWENewellis Inc
$ 2.76
(-33.49%)
73.39k
VWEVintage Wine Estates Inc
$ 0.0779
(-30.38%)
2.09M
VSTMVerastem Inc
$ 2.67
(-25.63%)
214.73k
ATPCAgape ATP Corporation
$ 0.16
(-25.58%)
869.51k
SLNASelina Hospitality PLC
$ 0.0259
(-0.38%)
41.4M
ALLRAllarity Therapeutics Inc
$ 0.2098
(26.01%)
38.06M
NUZENuZee Inc
$ 4.26
(313.59%)
24.19M
DRMADermata Therapeutics Inc
$ 3.45
(165.38%)
20.02M
HOTHHoth Therapeutics Inc
$ 1.43
(47.13%)
19.49M

INDP Discussion

View Posts
PonkenPlonken PonkenPlonken 2 months ago
" [...] Chief Medical Officer, Roger Waltzman, M.D., will present an update on the Company’s lead product candidate, Decoy20, at the 7th Annual Next-Gen Immuno-Oncology Conference in Boston on June 20-21, 2024.

Dr. Waltzman will present preliminary results from the Company’s ongoing Phase 1 study of Decoy20, an intravenous treatment using killed bacteria designed to broadly stimulate the immune system, in patients with advanced solid tumors.

Jeffrey Meckler, Indaptus CEO commented, “We are excited to share our latest findings from our Phase 1 clinical trial of Decoy20, and we are grateful for the opportunity to be invited to provide continued updates. We remain optimistic regarding the results seen to date and anticipate providing continued updates as they develop.”


$$$$
👍️0
PonkenPlonken PonkenPlonken 2 months ago
looks like its finally happening.
I dont mind them taking their time. Insiders are smart and know how to execute. See director Roger Pomerantz as per his LinkedIn:

"Led the development of 14 approved small and large molecule drugs, HIV, HCV, TB, CMV, and C Diff and Microbiome"

"Led and Completed over 160 Value-Creating Business Development, Licensing,
Acquisition and Partnership Deals (including large pharma with large pharma partnerships) at Tibotec Pharma, Johnson and Johnson, and Merck & Co, in Over 20 Diverse Therapeutic Areas, for Large and Small Molecules. Completed Deals and Partnerships in All Emerging Markets, eg. BRIC, especially in China"
👍️0
PonkenPlonken PonkenPlonken 2 months ago
people underestimate that Decoy is good for HBV and HIV too.
👍️0
Monksdream Monksdream 3 months ago
INDP under $3

👍️0
glenn1919 glenn1919 3 months ago
INDP...............................https://stockcharts.com/h-sc/ui?s=INDP&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 4 months ago
INDP under $3
👍️0
BurgerKing82 BurgerKing82 4 months ago
No one has posted on this board in 4-5 years?
👍️0
glenn1919 glenn1919 5 months ago
INDP............................................https://stockcharts.com/h-sc/ui?s=INDP&p=D&yr=0&mn=2&dy=12&id=p84071410134
👍️0
Awl416 Awl416 5 months ago
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort
👍️0
Jess070283 Jess070283 1 year ago
This thing warming up…
👍️0
heyitsmeagain heyitsmeagain 1 year ago
What are we thinking here
👍️0
subslover subslover 2 years ago
Indaptus Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors
NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for a Phase 1 clinical trial in patients with advanced solid tumors where currently approved therapies have failed. The Company plans to initiate the clinical trial in the second half of 2022.

“We are excited to begin our first in human study of Decoy20, as there is still a significant unmet medical need for patients with advanced solid tumors. This is an important milestone for Indaptus, which brings us one step closer to our goal of demonstrating the utility of a multi-targeted and antigen-agnostic, systemic immunotherapy that primes and activates both innate and adaptive anti-tumor immune responses,” said Jeffrey Meckler, Chief Executive Officer of Indaptus.

“Tumors remodel and inhibit systemic immune responses and Indaptus’ Decoy technology is unique in its ability to mobilize both innate and adaptive anti-tumor immune pathways with systemic administration in pre-clinical tumor models, while at the same time not inducing sustained hallmarks of cytokine release syndromes in pre-clinical toxicology studies,” said Dr. Michael Newman, Founder and Chief Scientific Officer of Indaptus.

“The trial is a Phase 1, open-label dose escalation and expansion study evaluating the safety, tolerability and preliminary efficacy of Decoy20 in patients with advanced solid tumors. We look forward to demonstrating the safety profile of Decoy20 and developing an effective, novel therapy for cancers unresponsive to existing approved therapies,” continued Mr. Meckler.

About the Phase 1 Study

The Phase 1 study is designed to evaluate the safety, tolerability, and preliminary efficacy of Decoy 20 and will follow a 3+3 design of dose-escalation cohorts. The study protocol allows for exploration of additional dosing regimens, including continuous weekly administration after initial safety has been established. Decoy20 has the potential to treat a wide range of solid tumors including hepatocellular, colorectal and pancreatic carcinomas.

About Indaptus Therapeutics

Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company’s approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Indaptus’ patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, with reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Decoy20 represents an antigen-agnostic technology that has produc
👍️0
alchemytrader alchemytrader 3 years ago
keeping on watch 5.80
👍️0
KnightTrader66 KnightTrader66 3 years ago
Presentation link. They now own Decoy Bios patents, since they merged.

https://indaptusrx.com/wp-content/uploads/2021/07/Decoy-Biosystems-PowerPoint-STING-TLR-Final-2021-05-26.pdf
👍️0
KnightTrader66 KnightTrader66 3 years ago
Lots of good DD here:

https://stocktwits.com/JacksrHi/message/413367374
👍️0
KnightTrader66 KnightTrader66 3 years ago
Where is everyone?
👍️0
Cubanwinner Cubanwinner 3 years ago
Pending a Mega bounce?
👍️0
Surfacetite Surfacetite 3 years ago
CEO bought $84k worth, not too bad.
👍️0
masterofdisaster masterofdisaster 3 years ago
This could be another IRNT
👍️0
SriMaharaj SriMaharaj 3 years ago
Today, I believe it will continue to go up not like yesterday that went up and down at the end of day.
👍️0
DeadCellShadix DeadCellShadix 3 years ago
Ya, I'm all out for a nice profit @ $14.30, had 1000 with $11.13 avg
👍️0
Surfacetite Surfacetite 3 years ago
it’s movin!
👍️0
Justfactsmam Justfactsmam 3 years ago
It's a simple explanation...The classic formula for Manipulated Pump in share price =

"micro-float stock + news (appears great but nothing of financial substance) that can cause unwarranted excitement then pop in SH (maybe even short covering)"

manipulated pump in share price

Likely pull back to $7.00... then lower when they do a secondary... Watch out for the price of secondary, if below $7.00 more pain.

There will likely be a lot of long-term holders who didn't intend to be...IMO...a long road ahead to breakeven for some.

glta...

Disclosure: watched the open...just saw the close...no position and no intention of initiating. Not my game.
👍️0
TheFinalCD TheFinalCD 3 years ago
10.10 wins
👍️0
TheFinalCD TheFinalCD 3 years ago
$2.6B dollar volume

was the news really that big?

ya wonder~!
👍️0
TheFinalCD TheFinalCD 3 years ago
also prev close was only 7.07 its still up +50+% from that

Message in reply to:

$INDP maybe they realized a patent isn't earth shaking
👍️0
TheFinalCD TheFinalCD 3 years ago
did you venture back in after that trade?
👍️0
TheFinalCD TheFinalCD 3 years ago
went lower than it opened= WOW 11.69-10.20


with the sickne$$
👍️0
makinezmoney makinezmoney 3 years ago
$INDP: Meltdown back to $11


Whatta day for this Schizo



GO $INDP
👍️0
$oldier Hard $oldier Hard 3 years ago
Think I'll let it settle down for awhile. Not giving any back.
👍️0
wickerman wickerman 3 years ago
$INDP maybe they realized a patent isn't earth shaking
👍️0
TheFinalCD TheFinalCD 3 years ago
your buy looked like a good one 11.69 low this is UNREAL


👍️0
TheFinalCD TheFinalCD 3 years ago
sometimes it bees like that...


👍️0
Up/DownTrader Up/DownTrader 3 years ago
What happened to all the "WEEEEEEEE--HAHAHAHAHA--KAAAABOOOOOM" over here, Dudes!!! GEEEEEEEEEEEEEEEEEEEZUUUUUSS what a dumping!!!!
👍️0
IloveTransformers1984 IloveTransformers1984 3 years ago
Lol, yes..still up a good chunk
👍️0
DeadCellShadix DeadCellShadix 3 years ago
Whelp, I’m in at $12.29.. probably made a mistake here.
👍️0
madras50 madras50 3 years ago
sorry to hear that. hope you're in the positive with the scalps.
👍️0
Surfacetite Surfacetite 3 years ago
some Patent crap, but now it’s dipping big time.

yeah i don’t get it, but to those that made off well like me, congrats!
👍️0
IloveTransformers1984 IloveTransformers1984 3 years ago
Damn I scalped 3 times this morning and tried again a 4th time and they burned me..
👍️0
madras50 madras50 3 years ago
scam news? wth happened?
👍️0
Surfacetite Surfacetite 3 years ago
oh man glad i sold in the $25s.
👍️0
TheFinalCD TheFinalCD 3 years ago
$12'S AGAIN ANY SHELF OR OTHER OFFERINGS?

INDP
👍️0
madras50 madras50 3 years ago
any news of offering? is that why the drop?
👍️0
TheFinalCD TheFinalCD 3 years ago
$13'S BACK AGAIN= WOOOOOOOOOW
👍️0
TheFinalCD TheFinalCD 3 years ago
15's from 28's


WOW SMH


$INDP REKT again massive loss. Stock didn't respect any support level at all was expecting bounce at 22, 18. Nothing. What a joke. Straight bullshit.— madaz (@madaznfootballr) September 15, 2021
👍️0
Zardiw Zardiw 3 years ago
Holy shit......lol

z
👍️0
cityimport cityimport 3 years ago
My best day in September so far ...

Let's GOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO........

👍️0
otterman otterman 3 years ago
Nice move. A lot of folks still averaging much higher thou. Need another good pop.
👍️0
cityimport cityimport 3 years ago
Another Round: 10,000 shares at 19 and out at 28.55 .. JUST BEATIFUL ...:))))))

More please... TODAY IS THE DAY... LOLzzzzz
👍️0
TheFinalCD TheFinalCD 3 years ago
$25= $$$$$$$$$$$$$$$$
👍️0

Your Recent History

Delayed Upgrade Clock